If you’ve been tracking deal flow across orthopedics, spine, and regenerative medicine over the past few months, you’ve probably noticed a distinct shift in how small and mid-tier companies are surviving.
The old playbook—raise venture money, build out a niche product line, hire 15 independent distributors, and wait for a top-five corporate takeout—is officially broken. Between high interest rates, aggressive hospital vendor consolidation, and the steady migration of surgeons into hospital employee models, the friction to scale alone is higher than ever.
Instead of burning cash to fight a headwind, we're seeing a wave of creative defensive and offensive consolidation: stock-and-cash mergers, PE-backed rollups, portfolio carve-outs, and strategic cross-licensing.
Below is my full breakdown of the four structural forces pushing companies together, case studies from recent 2026 transactions, and what this means for orthopedic founders going forward.
The Four Forces Driving the Compression
1. High Cost of Capital: Elevated interest rates have made cheap venture capital and easy debt relics of the past. The Federal Reserve has held the target rate at 3.50%–3.75% through mid-2026, keepi...
